An antibody to VEGF upregulates factor VIII via interleukin-1 in activated adrenal cortex-derived capillary endothelial cells

International Immunopharmacology

Volumn 3, Issue 4, 2003, Pages 493-512

  Li, Wenlu ^a,b   Keller, Gilbert A ^a  

^a GENENTECH INC   (United States)

^b diaDexus Inc   (United States)

Author keywords

Activated EC; Anti VEGF; FVIII; IL 1

Indexed keywords

BLOOD CLOTTING FACTOR 8; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; VASCULOTROPIN;

ADRENAL CORTEX; ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CAPILLARY ENDOTHELIUM; CARCINOGENESIS; CELL CULTURE; CELL SUBPOPULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; UPREGULATION; WOUND;

EID: 0037390494     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00002-X     Document Type: Article

References (63)

1. Weidner N., Semple J.P., Welch W., Folkman J. Tumor angiogenesis and metastasis. Correlation in invasive breast cancinoma. N. Engl. J. Med. 324:1991;1-8.
2. Horak E.R., Leek R., Klenk N., Lejeune S., Smith K.et al. Quantitative angiogenesis assessed by anti-PECAM antibodies: correlation with node metastasis and survival in breast cancer. Lancet. 340:1992;1120-1124.
3. Vartanian R.K., Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am. J. Pathol. 144:1994;1188-1194.
4. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
5. Folkman J. Tumor angiogenesis factor. Cancer Res. 34:1974;2109-2113.
6. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21:2000;505-515.
7. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18:1997;4-25.
8. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237:1999;97-132.
9. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 407:2000;242-248.
10. Shimada H., Takeda A., Nabeya Y., Okazumi S.I., Matsubara H.et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer. 92:2001;663-669.
11. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M.et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 77:1996;858-863.
12. Konno H., Abe J., Kaneko T., Baba M., Shoji A.et al. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn. J. Cancer Res. 92:2001;516-523.
13. Ikeda N., Nakajima Y., Sho M., Adachi M., Huang C.L.et al. The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer. 92:2001;488-499.
14. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A.et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann. Surg. Oncol. 8:2001;72-79.
15. West A.F., O'Donnell M., Charlton R.G., Neal D.E., Leung H.Y. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br. J. Cancer. 85:2001;576-583.
16. Toi M., Hoshima S., Takayanagi T., Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. 85:1994;1045-1049.
17. Kim K.J., Li B., Winer J., Armanini M., Gillett N.et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
18. Asano M., Yukita A., Matsumoto T., Hanatani M., Suzuki H. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma. 17:1998;185-190.
19. Kanai T., Konno H., Tanaka T., Baba M., Matsumoto K.et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int. J. Cancer. 77:1998;933-936.
20. Kondo S., Asano M., Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem. Biophys. Res. Commun. 194:1993;1234-1241.
21. Borgstrom P.G., Hillan D.P., Ferrara K.J., Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19:1999;4203-4214.
22. Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95:1995;1789-1797.
23. Giavazzi R., Taraboletti G. Angiogenesis and angiogenesis inhibitors in cancer. Forum. 9:1999;261-272.
24. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol. 11:2000;617-624.
25. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G.et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:1997;4593-4599.
26. Clark R.A.F. Overview and general considerations of wound repair. Clark R.A.F., Henson P.M. The molecular and cellular biology of wound repair. 1988;3-33 Plenum, New York.
27. Becker B.F., Heindl B., Kupatt C., Zahler S. Endothelial function and hemostasis. Kardil. 89:2000;160-167.
28. Folkman J. Angiogenesis: initiation and control. Ann. N. Y. Acad. Sci. 401:1982;212-227.
29. Grotendorst G.R. Chemoattractants and growth factors. Mitchell J. Wound healing: biochemical and clinical aspects. 1992;237-246 W.B. Saunders.
30. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1986;1650-1659.
31. Croix B.S., Rago C., Velculescu V., Traverso G., Romans K.E.et al. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
32. Coomber B.L., Gotlieb A.I. In vitro endothelial wound repair - interaction of cell migration and proliferation. Arteriosclerosis. 10:1990;215-222.
33. Gotlieb A.I., McBurnie M.L., Subrahmanyan L., Kalnins V.I. Distribution of microtubule organizing centers in migrating sheets of endothelial cells. J. Cell Biol. 91:1981;589-594.
34. Sammak P.J., Hinman L.E., Tran P.O.T., Sjaastad M.D., Machen T.E. How do injured cells communicate with the surviving cell monolayer? J. Cell Sci. 110:1997;465-475.
35. Kwak B.R., Pepper M.S., Gros D.B., Meda P. Inhibition of endothelial wound repair by dominant negative connexin inhibitors. Mol. Biol. Cell. 12:2001;831-845.
36. Li W., Keller G.A. VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. J. Cell Sci. 113:2000;1525-1534.
37. Walter D.H., Hink U., Asahara T., Van Belle E., Horowitz J.et al. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation. Lab. Invest. 74:1996;546-556.
38. Ghitescu L., Robert M. Diversity in unity: the biochemical composition of the endothelial cell surface varies between the vascular beds. Microsc. Res. Tech. 57:2002;381-389.
39. Thorin E., Shreeve S.M. Heterogeneity of vascular endothelial cells in normal and disease states. Pharmacol. Ther. 78:1998;155-166.
40. Craig L.E., Spelman J.P., Strandberg J.D., Zink M.C. Endothelial cells from diverse tissues exhibit differences in growth and morphology. Microvasc. Res. 55:1998;65-76.
41. Chen Y., Wiesmann C., Fuh G., Li B., Christinger H.W.et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293:1999;865-881.
42. Symons J.A., Young P.R., Duff G.W. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1b precursor and loses affinity for IL-1 receptor antagonist. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1714-1718.
43. Slack J., McMahan C.J., Waugh S., Schooley K., Spriggs M.K.et al. Independent binding or interleukin-1a and interleukin-1b to type I and type II interleukin-1 receptors. J. Biol. Chem. 268:1993;2513-2524.
44. de Bandt M., Ollivier V., Meyer O., Babin-Chevaye C., Khechai F.et al. Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells. Arthritis Rheum. 40:1997;2030-2038.
45. del Papa N., Guidali L., Sironi M., Shenfeld Y., Mantovani A.et al. Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis Rheum. 39:1996;758-766.
46. Abramovitch R., Neeman M., Reich R., Stein I., Keshet E.et al. Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor. FEBS Lett. 425:1998;441-447.
47. Sims J.E., Gayle M.A., Slack J.L., Alderson M.R., Bird T.A.et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl. Acad. Sci. U. S. A. 1993;6155-6159.
48. Deng S.X., Hanson E., Sanz I. In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies. Int. Immunol. 12:2000;415-423.
49. Vlahakos D.V., Foster M.H., Ucci A.A., Berrett K.J., Datta S.K., Madaio M.P. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei and induce glomerular proliferation and proteinuria in vivo. J. Am. Soc. Nephrol. 2:1992;1345-1354.
50. Yanase K., Smith R.M., Cizman B., Foster M.H., Peachey L.D.et al. A subgroup of murine monoclonal anti-DNA antibodies traverse the cytoplasm and enter the nucleus in a time and temperature dependent manner. Lab. Invest. 71:1994;52-60.
51. Madaio M.P., Yanase K. Cellular penetration and nuclear localization of anti-DNA antibodies: mechanisms, consequences, implications and applications. J. Autoimmun. 11:1998;535-538.
52. Sica A., Matsushima K., Van Damme J., Wang J.M., Polentarutti N.et al. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology. 69:1990;548-553.
53. Sironi M., Breviario F., Proserpio P., Biondi A., Vecchi A.et al. IL-1 stimulates IL-6 production in endothelial cells. J. Immunol. 142:1989;549-553.
54. Nawroth P.P., Handley D.A., Esmon C.T., Stern D.M. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc. Natl. Acad. Sci. U. S. A. 83:1986;3460-3464.
55. Mantovani A., Bussolino F., Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 6:1992;2591-2599.
56. Dosquet C., Weill D., Wautier J.-L. Cytokines and thrombosis. J. Cardiovasc. Pharmacol. 25:1995;S13-S19.
57. Krishnaswamy G., Kelley J., Yerra L., Smith J.K., Chi D.S. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 19:1999;91-104.
58. Arend W.P., Malyak M., Smith M.F., Whisenand T.D., Slack J.L.et al. Binding of IL-1a, IL-1b, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J. Immunol. 153:1994;4766-4774.
59. Symons J.A., Young P.A., Duff G.W. Differential release and ligand binding of type II IL-1 receptors. Cytokine. 6:1994;555.
60. Dinarello C.A. Interleukin-1. Cytokine Growth Factor Rev. 4:1997;253-265.
61. Dinarello C. Biological basis for interleukin-1 in diseases. Blood. 87:1996;2095-2147.
62. Fantuzzi G., Dinarello C.A. The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J. Leukoc. Biol. 59:1996;489-493.
63. Abramovitch R., Marikovsky M., Meir G., Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br. J. Cancer. 79:1998;1392-1398.